Antiviral efficacy and resistance in patients on antiretroviral therapy in Kigali, Rwanda: The real-life situation in 2002

HIV Medicine

Volumn 7, Issue 1, 2006, Pages 64-66

  Fischer, Aurelie ^a   Karasi, J C ^b   Kibibi, D ^b   Omes, C ^b   Lambert, C ^a   Uwayitu, A ^b   Hemmer, R ^a   Van Den Ende, J ^c   Schmit, J C ^a   Arendt, V ^a  

^a CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^b Centre Hospitalier Universitaire de Kigali   (Rwanda)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE ACCESS; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; RWANDA; SOCIOECONOMICS; VIRUS LOAD; VIRUS MUTATION;

EID: 33645978407     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2005.00338.x     Document Type: Article

References (7)

1. Vergne L, Malonga-Mouellet G, Mistoul I et al. Resistance to antiretroviral treatment in Gabon: Need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 2002; 29: 165-168.
2. Weidle P, Downing R, Sozi C et al. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV drug access initiative - Uganda. AIDS 2003; 17 (Suppl. 3): S39-S48.
3. Landman R, Schiemann R, Thiam S et al. Once-a-day highly active antiretroviral therapy in treatment-naïve HIV-1-infected adults in Senegal. AIDS 2003; 17: 1017-1022.
4. Laurent C, Diakhate N, Gueye NF et al. The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 2002; 16: 1363-1370.
5. Servais J, Lambert C, Karita E et al. HIV-1 Pol gene diversity and archived Nevirapine resistance mutations in pregnant women in Rwanda. AIDS Res Hum Retroviruses 2004; 20: 279-283.
6. Frater AJ, Beardall A, Ariyoshi K et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15: 1493-1502.
7. Velazquez-Campoy A, Todd MJ, Vega S, Freire E. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci USA 2001; 98: 6062-6067.